{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T05:52:55Z","timestamp":1787032375766,"version":"build-2736575974"},"reference-count":40,"publisher":"Harborside Press, LLC","issue":"8","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>\n                    <jats:bold>Background:<\/jats:bold>\n                    There is limited research on the burden and outcomes of patients diagnosed with metastatic castration-resistant prostate cancer (mCRPC), which may result in limited understanding of the disease and lead to suboptimal disease management. Using a validated algorithm to identify mCRPC disease onset, this study offers the first comprehensive description of mCRPC among veterans nationwide.\n                    <jats:bold>Methods:<\/jats:bold>\n                    The study used data from the Veterans Health Administration\u2019s Corporate Data Warehouse. Participants were identified using the Prostate Datacore, which uses structured data and natural language processing to identify veterans with prostate cancer, metastatic prostate cancer, and mCRPC. We calculated prevalence and age-adjusted incidence rates of mCRPC from 2005 to 2022 and performed Mann-Kendall trend tests to analyze statistical trends within the time series data. We performed a time-to-event analysis to calculate the median time to mCRPC by disease course, as well as a survival analysis from the date of mCRPC diagnosis to death.\n                    <jats:bold>Results:<\/jats:bold>\n                    We identified 44,246 patients with mCRPC. Prevalence, incidence, and survival increased each year, with the highest prevalence in the western United States. In 2022, the age-adjusted incidence rate was 5 per 1,000 prostate cancer cases. Median time to mCRPC from prostate cancer diagnosis was 5.68 years in patients with de novo disease and 10.98 years in patients with disease progression from localized stages. Median overall survival increased from 1.23 years (95% CI, 1.19\u20131.27) in 2005 to 2011, to 1.75 years (95% CI, 1.70\u20131.80) in 2012 to 2017, to 2.17 years (95% CI, 2.11\u20132.22) in 2018 to 2024, and with differences observed across age groups (\n                    <jats:italic>P<\/jats:italic>\n                    &lt;.05). Trends show increasing age, Charlson comorbidity index score, and body mass index at diagnosis, but decreasing prostate-specific antigen levels per year.\n                    <jats:bold>Conclusions:<\/jats:bold>\n                    This study describes veterans with mCRPC, suggests that survival and diagnostic methods are improving, and emphasizes the need for better disease management strategies to delay progression to and enhance treatment of mCRPC in order to further prolong survival.\n                  <\/jats:p>","DOI":"10.6004\/jnccn.2025.7032","type":"journal-article","created":{"date-parts":[[2025,7,14]],"date-time":"2025-07-14T18:14:00Z","timestamp":1752516840000},"page":"307-313","source":"Crossref","is-referenced-by-count":4,"title":["Epidemiology of Metastatic Castration-Resistant Prostate Cancer in Veterans Nationwide"],"prefix":"10.6004","volume":"23","author":[{"given":"Danielle","family":"Candelieri-Surette","sequence":"first","affiliation":[{"name":"University of Massachusetts Lowell, Lowell, MA"},{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"JongSoo","family":"Lee","sequence":"additional","affiliation":[{"name":"University of Massachusetts Lowell, Lowell, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie A.","family":"Lynch","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nai-Chung N.","family":"Chang","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tyler J.","family":"Nelson","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Craig C.","family":"Teerlink","sequence":"additional","affiliation":[{"name":"VA Informatics and Computing Infrastructure, VA Salt Lake City Health Care System, Salt Lake City, UT"},{"name":"Division of Epidemiology, Department of Internal Medicine, University of Utah School of Medicine, Salt Lake City, UT"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Camilla","family":"Pimentel","sequence":"additional","affiliation":[{"name":"University of Massachusetts Lowell, Lowell, MA"},{"name":"Center for Healthcare Organization and Implementation Research, VA Bedford Healthcare System, Bedford, MA"},{"name":"New England Geriatric Research Education and Clinical Center, VA Bedford Healthcare System, Bedford, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin W.","family":"Schoen","sequence":"additional","affiliation":[{"name":"Medicine Service, St. Louis Veterans Affairs Health Care System, Saint Louis, MO"},{"name":"Division of Hematology\/Oncology, Department of Internal Medicine, Saint Louis University School of Medicine, Saint Louis, MO"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan","family":"Berlowitz","sequence":"additional","affiliation":[{"name":"University of Massachusetts Lowell, Lowell, MA"},{"name":"Boston University School of Medicine, Boston, MA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","article-title":"Key statistics for prostate cancer","unstructured":"American Cancer Society. Key statistics for prostate cancer. Accessed March 21, 2025. Available at: https:\/\/www.cancer.org\/cancer\/types\/prostate-cancer\/about\/key-statistics.html"},{"key":"B2","series-title":"Cancer","first-page":"2311","article-title":"Factors influencing treatment of veterans with advanced prostate cancer","volume":"127","author":"Caram MEV","year":"2021","unstructured":"Caram MEV, Burns J, Kumbier K,  Factors influencing treatment of veterans with advanced prostate cancer. Cancer 2021;127:2311\u20132318."},{"key":"B3","series-title":"Cancer Epidemiol Biomarkers Prev","first-page":"1740","article-title":"Cancer incidence in the U.S. military population: comparison with rates from the SEER program","volume":"18","author":"Zhu K","year":"2009","unstructured":"Zhu K, Devesa SS, Wu H,  Cancer incidence in the U.S. military population: comparison with rates from the SEER program. Cancer Epidemiol Biomarkers Prev 2009;18:1740\u20131745."},{"key":"B4","series-title":"J Clin Oncol","first-page":"Abstract 210.","article-title":"Healthy lifestyle, Agent Orange exposure, and inherited PCa risk: an analysis of the Million Veteran Program","volume":"41","author":"Pagadala M","year":"2023","unstructured":"Pagadala M, Lui A, Lynch JA,  Healthy lifestyle, Agent Orange exposure, and inherited PCa risk: an analysis of the Million Veteran Program. J Clin Oncol 2023;41(Suppl 6):Abstract 210."},{"key":"B5","series-title":"Int J Clin Pract","first-page":"1180","article-title":"Characterising the castration-resistant prostate cancer population: a systematic review","volume":"65","author":"Kirby M","year":"2011","unstructured":"Kirby M, Hirst C, Crawford ED. Characterising the castration-resistant prostate cancer population: a systematic review. Int J Clin Pract 2011;65:1180\u20131192."},{"key":"B6","series-title":"Prostate Cancer Prostatic Dis","first-page":"811","article-title":"Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases","volume":"26","author":"Schoen MW","year":"2023","unstructured":"Schoen MW, Carson KR, Eisen SA,  Survival of veterans treated with enzalutamide and abiraterone for metastatic castrate resistant prostate cancer based on comorbid diseases. Prostate Cancer Prostatic Dis 2023;26:811."},{"key":"B7","series-title":"Cancer Drug Resist","first-page":"742","article-title":"Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms","volume":"3","author":"Verma S","year":"2020","unstructured":"Verma S, Prajapati KS, Kushwaha PP,  Resistance to second generation antiandrogens in prostate cancer: pathways and mechanisms. Cancer Drug Resist 2020;3:742\u2013761."},{"key":"B8","series-title":"JAMA","first-page":"975","article-title":"Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer","volume":"280","author":"Albertsen PC","year":"1998","unstructured":"Albertsen PC, Hanley JA, Gleason DF, Barry MJ. Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA 1998;280:975\u2013980."},{"key":"B9","series-title":"Int J Urol","first-page":"220","article-title":"Current treatment strategies for advanced prostate cancer","volume":"25","author":"Komura K","year":"2018","unstructured":"Komura K, Sweeney CJ, Inamoto T,  Current treatment strategies for advanced prostate cancer. Int J Urol 2018;25:220\u2013231."},{"key":"B10","series-title":"Cancer Res","first-page":"3081","article-title":"Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease","volume":"65","author":"Lin B","year":"2005","unstructured":"Lin B, White JT, Lu W,  Evidence for the presence of disease-perturbed networks in prostate cancer cells by genomic and proteomic analyses: a systems approach to disease. Cancer Res 2005;65:3081\u20133091."},{"key":"B11","series-title":"Oncologist","first-page":"110","article-title":"Rational second-generation antiandrogen use in prostate cancer","volume":"27","author":"Orme JJ","year":"2022","unstructured":"Orme JJ, Pagliaro LC, Quevedo JF,  Rational second-generation antiandrogen use in prostate cancer. Oncologist 2022;27:110\u2013124."},{"key":"B12","series-title":"Eur Urol","first-page":"467","article-title":"EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer","volume":"65","author":"Heidenreich A","year":"2014","unstructured":"Heidenreich A, Bastian PJ, Bellmunt J,  EAU guidelines on prostate cancer. Part II: treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014;65:467\u2013479."},{"key":"B13","article-title":"2023 ICD-10-CM diagnosis code Z19.2: hormone resistant malignancy status","author":"ICD10Data.com","unstructured":"ICD10Data.com. 2023 ICD-10-CM diagnosis code Z19.2: hormone resistant malignancy status. Accessed March 21, 2025. Available at: https:\/\/www.icd10data.com\/ICD10CM\/Codes\/Z00-Z99\/Z19-Z19\/Z19-\/Z19.2"},{"key":"B14","series-title":"J Clin Oncol","first-page":"Abstract 72","article-title":"Diagnosis codes overestimate the burden of prostate cancer cases","volume":"40","author":"Anglin-Foote T","year":"2022","unstructured":"Anglin-Foote T, Lee KM, Robison B,  Diagnosis codes overestimate the burden of prostate cancer cases. J Clin Oncol 2022;40(Suppl 6):Abstract 72."},{"key":"B15","series-title":"Fed Pract","first-page":"S32","article-title":"Prostate Cancer Foundation-Department of Veterans Affairs partnership: a model of public-private collaboration to advance treatment and care of invasive cancers","volume":"37","author":"Levine RD","year":"2020","unstructured":"Levine RD, Ekanayake RN, Martin AC,  Prostate Cancer Foundation-Department of Veterans Affairs partnership: a model of public-private collaboration to advance treatment and care of invasive cancers. Fed Pract 2020;37(Suppl 4):S32\u201337."},{"key":"B16","series-title":"JCO Clin Cancer Inform","first-page":"e2300085.","article-title":"Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer","volume":"7","author":"Candelieri-Surette D","year":"2023","unstructured":"Candelieri-Surette D, Hung A, Lynch J, Pridgen,  Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer. JCO Clin Cancer Inform 2023;7:e2300085."},{"key":"B17","article-title":"VA Informatics and Computing Infrastructure (VINCI) VA HSR RES 13-457","author":"VA Prostate Data Core","unstructured":"VA Prostate Data Core. VA Informatics and Computing Infrastructure (VINCI) VA HSR RES 13-457. Accessed January 3, 2024. Available at: https:\/\/www.research.va.gov\/programs\/vinci\/"},{"key":"B18","series-title":"JCO Clin Cancer Inform","first-page":"1005","article-title":"Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing","volume":"5","author":"Alba PR","year":"2021","unstructured":"Alba PR, Gao A, Lee KM,  Ascertainment of veterans with metastatic prostate cancer in electronic health records: demonstrating the case for natural language processing. JCO Clin Cancer Inform 2021;5:1005\u20131014."},{"key":"B19","series-title":"JCO Clin Cancer Inform","first-page":"e2300085.","article-title":"Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer","volume":"7","author":"Candelieri-Surette D","year":"2023","unstructured":"Candelieri-Surette D, Hung A, Lynch JA,  Development and validation of a tool to identify patients diagnosed with castration-resistant prostate cancer. JCO Clin Cancer Inform 2023;7:e2300085."},{"key":"B20","series-title":"APMIS","first-page":"433","article-title":"International Society of Urological Pathology (ISUP) grading of prostate cancer \u2013 an ISUP consensus on contemporary grading","volume":"124","author":"Egevad L","year":"2016","unstructured":"Egevad L, Delahunt B, Srigley JR, Samaratunga H. International Society of Urological Pathology (ISUP) grading of prostate cancer \u2013 an ISUP consensus on contemporary grading. APMIS 2016;124:433\u2013435."},{"key":"B21","article-title":"Veterans Affairs Central Cancer Registry (VACCR)","author":"U.S. Department of Veteran Affairs","unstructured":"U.S. Department of Veteran Affairs. Veterans Affairs Central Cancer Registry (VACCR). Accessed March 21, 2025. Available at: https:\/\/www.data.va.gov\/dataset\/Veterans-Affairs-Central-Cancer-Registry-VACCR-\/jvmd-8fgj\/about_data"},{"key":"B22","series-title":"J Chronic Dis","first-page":"373","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson ME","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987;40:373\u2013383."},{"key":"B23","series-title":"Am J Epidemiol","first-page":"676","article-title":"Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries","volume":"173","author":"Quan H","year":"2011","unstructured":"Quan H, Li B, Couris CM,  Updating and validating the Charlson comorbidity index and score for risk adjustment in hospital discharge abstracts using data from 6 countries. Am J Epidemiol 2011;173:676\u2013682."},{"key":"B24","series-title":"J Nucl Med","first-page":"733","article-title":"Update on 18F-fluciclovine PET for prostate cancer imaging","volume":"59","author":"Parent EE","year":"2018","unstructured":"Parent EE, Schuster DM. Update on 18F-fluciclovine PET for prostate cancer imaging. J Nucl Med 2018;59:733\u2013739."},{"key":"B25","series-title":"J Nucl Med Technol","first-page":"9","article-title":"18F-sodium fluoride PET: history, technical feasibility, mechanism of action, normal biodistribution, and diagnostic performance in bone metastasis detection compared with other imaging modalities","volume":"48","author":"Ahuja K","year":"2020","unstructured":"Ahuja K, Sotoudeh H, Galgano SJ,  18F-sodium fluoride PET: history, technical feasibility, mechanism of action, normal biodistribution, and diagnostic performance in bone metastasis detection compared with other imaging modalities. J Nucl Med Technol 2020;48:9\u201316."},{"key":"B26","article-title":"Everything you wanted to know about prostate cancer, but were afraid to ask","author":"Zick S","unstructured":"Zick S. Everything you wanted to know about prostate cancer, but were afraid to ask. Accessed March 21, 2025. Available at: https:\/\/www.va.gov\/greater-los-angeles-health-care\/stories\/everything-you-wanted-to-know-about-prostate-cancer-but-were-afraid-to-ask\/"},{"key":"B27","series-title":"N Engl J Med","first-page":"1604","article-title":"The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer","volume":"312","author":"Feinstein AR","year":"1985","unstructured":"Feinstein AR, Sosin DM, Wells CK. The Will Rogers phenomenon. Stage migration and new diagnostic techniques as a source of misleading statistics for survival in cancer. N Engl J Med 1985;312:1604\u20131608."},{"key":"B28","article-title":"Xtandi FDA approval history","author":"Drugs.com","unstructured":"Drugs.com. Xtandi FDA approval history. Accessed March 21, 2025. Available at: https:\/\/www.drugs.com\/history\/xtandi.html"},{"key":"B29","article-title":"Zytiga FDA approval history","author":"Drugs.com","unstructured":"Drugs.com. Zytiga FDA approval history. Accessed March 21, 2025. Available at: https:\/\/www.drugs.com\/history\/zytiga.html"},{"key":"B30","article-title":"Jevtana FDA approval history","author":"Drugs.com","unstructured":"Drugs.com. Jevtana FDA approval history. Accessed March 21, 2025. Available at: https:\/\/www.drugs.com\/history\/jevtana.html"},{"key":"B31","series-title":"J Clin Oncol","first-page":"Abstract 81","article-title":"Characterization and survival benefit of drugs approved for metastatic prostate cancer","volume":"41","author":"Benjamin DJ","year":"2023","unstructured":"Benjamin DJ, Rezazadeh A. Characterization and survival benefit of drugs approved for metastatic prostate cancer. J Clin Oncol 2023;41(Suppl 6):Abstract 81."},{"key":"B32","article-title":"NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2","author":"Mohler JL","year":"2019","unstructured":"Mohler JL, Antonarakis ES, Armstrong AJ,  NCCN Clinical Practice Guidelines in Oncology: Prostate Cancer. Version 2.2019. To view the most recent version, visit https:\/\/www.nccn.org"},{"key":"B33","series-title":"JAMA Netw Open","first-page":"e222246.","article-title":"Trends in incidence of metastatic prostate cancer in the US","volume":"5","author":"Desai MM","year":"2022","unstructured":"Desai MM, Cacciamani GE, Gill K,  Trends in incidence of metastatic prostate cancer in the US. JAMA Netw Open 2022;5:e222246."},{"key":"B34","series-title":"J Natl Cancer Inst","first-page":"64","article-title":"Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening","volume":"113","author":"Jemal A","year":"2021","unstructured":"Jemal A, Culp MB, Ma J,  Prostate cancer incidence 5 years after US Preventive Services Task Force recommendations against screening. J Natl Cancer Inst 2021;113:64\u201371."},{"key":"B35","series-title":"JCO Clin Cancer Inform","first-page":"1059","article-title":"Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors","volume":"4","author":"Patt D","year":"2020","unstructured":"Patt D, Gordan L, Diaz M,  Impact of COVID-19 on cancer care: how the pandemic is delaying cancer diagnosis and treatment for American seniors. JCO Clin Cancer Inform 2020;4:1059\u20131071."},{"key":"B36","series-title":"BMJ Support Palliat Care.","article-title":"COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review","author":"Mostafavi Zadeh SM","year":"2023","unstructured":"Mostafavi Zadeh SM, Tajik F, Gheytanchi E,  COVID-19 pandemic impact on screening and diagnosis of prostate cancer: a systematic review. BMJ Support Palliat Care. Published online September 25, 2023. doi:10.1136\/spcare-2023-004310"},{"key":"B37","series-title":"Cancers (Basel)","first-page":"3490.","article-title":"Advanced imaging for localized prostate cancer","volume":"16","author":"Albers P","year":"2024","unstructured":"Albers P, Kinnaird A. Advanced imaging for localized prostate cancer. Cancers (Basel) 2024;16:3490."},{"key":"B38","series-title":"JAMA Netw Open","first-page":"e2414582.","article-title":"Access to prostate-specific antigen testing and mortality among men with prostate cancer","volume":"7","author":"Iyer HS","year":"2024","unstructured":"Iyer HS, Stone BV, Roscoe C,  Access to prostate-specific antigen testing and mortality among men with prostate cancer. JAMA Netw Open 2024;7:e2414582."},{"key":"B39","series-title":"JAMA Netw Open","first-page":"e2432288.","article-title":"COVID-19 and rates of cancer diagnosis in the US","volume":"7","author":"Burus T","year":"2024","unstructured":"Burus T, Lei F, Huang B,  COVID-19 and rates of cancer diagnosis in the US. JAMA Netw Open 2024;7:e2432288."},{"key":"B40","series-title":"BJU Int","first-page":"587","article-title":"During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England","volume":"133","author":"Lemanska A","year":"2024","unstructured":"Lemanska A, Andrews C, Fisher L,  During the COVID-19 pandemic 20 000 prostate cancer diagnoses were missed in England. BJU Int 2024;133:587\u2013595."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/8\/article-p307.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/8\/article-p307.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/8\/article-p307.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:36:37Z","timestamp":1754397397000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/8\/article-p307.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":40,"journal-issue":{"issue":"8"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7032","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8]]}}}